1. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353–365. [PubMed] [Google Scholar]
2. (USRDS) USRDS . In: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, editor. Bethesda, MD: 2008. [Google Scholar]
3. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. Kidney Int. 2005;68:S7–S10. [PubMed] [Google Scholar]
4. Staples AO, Smith JC, Gipson DS, Wong CS, Filler G, Warady B, Martz K, Greenbaum LA. Risk factors associated with progression of pediatric chronic kidney disease. 2007 E-PAS2007:61:7919.5. [Google Scholar]
5. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the national kidney foundation. Am J Kidney Dis. 2007;50:169–180. [PubMed] [Google Scholar]
6. Wong CS, Mak RHK. Chronic kidney disease. In: Kher KK, Schnapper HW, Makker SP, editors. Clinical Pediatric Nephrology. Informa UK Ltd; 2007. pp. 339–352. [Google Scholar]
7. Sanna-Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R, Piaggio G, Innocenti ML, Somenzi D, Trivelli A, Caridi G, et al. Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int. 2009;76:528–533. [PubMed] [Google Scholar]••
Observational study with long-term outcomes demonstrating the increased risk for end-stage renal disease of children with a congenital solitary kidney and of children with hypodysplasia.
8. Chesney RW. The future of pediatric nephrology. Pediatr Nephrol. 2005;20:867–871. [PubMed] [Google Scholar]
9. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266. [PubMed] [Google Scholar]
10. Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, Marra G, Edefonti A, Sereni F. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics. 2003;111:e382–387. [PubMed] [Google Scholar]
11. Strict Blood-Pressure Control and Progression of Renal Failure in Children. N Engl J Med. 2009;361:1639–1650. [PubMed] [Google Scholar]••
This interventional study demonstrates the benefit of intensified blood pressure control to slow CKD progression in children with CKD.
12. Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA. Design and Methods of the Chronic Kidney Disease in Children (CKiD) Prospective Cohort Study. Clin J Am Soc Nephrol. 2006;1:1006–1015. [PMC free article] [PubMed] [Google Scholar]
13. Soares CM, Oliveira EA, Diniz JS, Lima EM, Vasconcelos MM, Oliveira GR. Predictive factors of progression of chronic renal insufficiency: a multivariate analysis. Pediatr Nephrol. 2003;18:371–377. [PubMed] [Google Scholar]
14. Hogg RJ, Furth S, KV L, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416. [PubMed] [Google Scholar]
15. Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A. Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int. 2006;69:2070–2077. [PubMed] [Google Scholar]
16. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol. 1995;6:257–263. [PubMed] [Google Scholar]
17. Schwartz GJ, Furth S. Safety of Plasma Clearance of Iohexol to Measure GFR. Personal communication. 2009 [Google Scholar]
18. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–637. [PMC free article] [PubMed] [Google Scholar]••
This is an update of GFR estimating equations based on clinical and laboratory measurements using the GFR by iohexol plasma disappearance as the gold standard.
19. Abraham AG, Schwartz GJ, Furth S, Warady BA, Munoz A. Longitudinal Formulas to Estimate GFR in Children with CKD. Clin J Am Soc Nephrol. 2009 [PMC free article] [PubMed] [Google Scholar]
20. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762. [PubMed] [Google Scholar]
21. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet. 1997;349:1857–1863. [PubMed] [Google Scholar]
22. Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, Procaccio M, Avolio L, Ciofani A, Dello Strologo L, et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project Pediatr Nephrol. 2004;19:172–177. [PubMed] [Google Scholar]
23. Wuhl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–776. [PubMed] [Google Scholar]
24. Ellis D, Moritz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens. 2004;17:928–935. [PubMed] [Google Scholar]
25. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol. 2005;64:35–40. [PubMed] [Google Scholar]
26. Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL, Schwartz GJ. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol. 2009;4:812–819. [PMC free article] [PubMed] [Google Scholar]•
This study evaluates the determinants of proteinuria among children with CKD.
27. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant. 1996;11:461–467. [PubMed] [Google Scholar]
28. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18. [PubMed] [Google Scholar]
29. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) J Am Soc Nephrol. 2003;14:2618–2622. [PubMed] [Google Scholar]
30. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet. 1997;349:1117–1123. [PubMed] [Google Scholar]
31. Wuhl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol. 2008;23:705–716. [PMC free article] [PubMed] [Google Scholar]
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. [PubMed] [Google Scholar]
33. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag. 2007;3:783–795. [PMC free article] [PubMed] [Google Scholar]
34. Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension. 2008;52:631–637. [PMC free article] [PubMed] [Google Scholar]•
This study from the CKiD group identifies that there are barriers to achieving controlled blood pressure and assesses the determinants for controlled and uncontrolled blood pressure.
35. Chandra M, McVicar M, Clemons GK. Pathogenesis of the anemia of chronic renal failure: the role of erythropoietin. Adv Pediatr. 1988;35:361–389. [PubMed] [Google Scholar]
36. Wong H, Mylrea K, Feber J, Drukker A, Filler G. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int. 2006;70:585–590. [PubMed] [Google Scholar]
37. Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:48–56. [PMC free article] [PubMed] [Google Scholar]•
This study demonstrates the increased risk of hospitalization associated with anemia in children with CKD and shows no association between increased risk of morbidity and normalized hematocrit levels.
38. Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol. 2008;3:457–462. [PMC free article] [PubMed] [Google Scholar]•
Demonstrates that there is a threshold of GFR in children with CKD when the rate of anemia becomes more pronounced.
39. Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol. 2006;17:2878–2885. [PubMed] [Google Scholar]
40. Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 2003;18:1055–1062. [PubMed] [Google Scholar]
41. Furth SL, Cole SR, Fadrowski JJ, Gerson A, Pierce CB, Chandra M, Weiss R, Kaskel F. The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. Pediatr Nephrol. 2007;22:265–271. [PubMed] [Google Scholar]
42. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–185. [PubMed] [Google Scholar]
43. Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738–750. [PubMed] [Google Scholar]
44. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084. [PubMed] [Google Scholar]
45. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189. [PubMed] [Google Scholar]
46. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098. [PubMed] [Google Scholar]
47. Burke JR. Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. Pediatr Nephrol. 1995;9:558–561. [PubMed] [Google Scholar]
48. Montini G, Zacchello G, Baraldi E, Zanconato S, Suppiej A, Fabris F, Andreetta B, Pavanello L, Zacchello F. Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr. 1990;117:556–560. [PubMed] [Google Scholar]
49. Abitbol CL, Chandar J, Rodriguez MM, Berho M, Seeherunvong W, Freundlich M, Zilleruelo G. Obesity and preterm birth: additive risks in the progression of kidney disease in children. Pediatr Nephrol. 2009;24:1363–1370. [PubMed] [Google Scholar]••
This retrospective single center study provides compelling data regarding the increased risk for CKD in individuals who are born pre-term. The evaluation of obesity in their study demonstrated that obese patients who were preterm infants had a more rapid decline in kidney function compared to obese patients who were born at term.
50. Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol. 2008;19:151–157. [PMC free article] [PubMed] [Google Scholar]••
Cohort study with registry data with long-term follow-up in Norway demonstrates the increased risk of low birth weight and end-stage renal disease.
51. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18:526–530. [PMC free article] [PubMed] [Google Scholar]
52. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924–932. [PMC free article] [PubMed] [Google Scholar]••
This interventional study with allopurinol provides a possible mechanism by which elevated serum uric acid levels are associated with CKD progression.
53. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169:342–350. [PMC free article] [PubMed] [Google Scholar]••
This is a population based retrospective cohort study that identified multiple risk factors associated with ESRD. The most important risk factors identified by the authors were proteinuria and excess weight. Other risk factors of interest included: lower hemoglobin level, higher uric acid level, self-reported history of nocturia, and family history of kidney disease.
54. Lin JL, Lin-Tan DT, Li YJ, Chen KH, Huang YL. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med. 2006;119:707, e701–709. [PubMed] [Google Scholar]
55. Muntner P, He J, Vupputuri S, Coresh J, Batuman V. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int. 2003;63:1044–1050. [PubMed] [Google Scholar]
56. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301. [PubMed] [Google Scholar]
57. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075–2084. [PMC free article] [PubMed] [Google Scholar]••
Randomized open-label, prospective parallel-group study of bicarbonate supplementation in adults with CKD. Intervention subjects had a slower decline in creatinine clearance and improved nutritional status compared to control subjects.
58. Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr Nephrol. 2009 [PubMed] [Google Scholar]
59. Norman LJ, Macdonald IA, Watson AR. Optimising nutrition in chronic renal insufficiency--progression of disease. Pediatr Nephrol. 2004;19:1253–1261. [PubMed] [Google Scholar]
60. Ritz E, Gross ML, Dikow R. Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int Suppl. 2005:S66–70. [PubMed] [Google Scholar]
61. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75:88–95. [PubMed] [Google Scholar]••
This prospective observational cohort study among adult patients with CKD demonstrates that low serum vitamin D levels are associated with a higher risk for CKD progression and death.
62. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, Bowden DW, Duggirala R, Elston RC, Hanson RL, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND) Diabetes. 2007;56:1577–1585. [PubMed] [Google Scholar]
63. Freedman BI, Bowden DW, Rich SS, Xu J, Wagenknecht LE, Ziegler J, Hicks PJ, Langefeld CD. Genome-wide linkage scans for renal function and albuminuria in Type 2 diabetes mellitus: the Diabetes Heart Study. Diabet Med. 2008;25:268–276. [PubMed] [Google Scholar]
64. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2:1306–1316. [PubMed] [Google Scholar]
65. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, Rich SS, Freedman BI. A genome scan for diabetic nephropathy in African Americans. Kidney Int. 2004;66:1517–1526. [PubMed] [Google Scholar]
66. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184. [PMC free article] [PubMed] [Google Scholar]••
Identification of MYH9 as a novel gene associated with primary and secondary forms of focal segmental sclerosis.
67. Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS, Polasek O, Kolcic I, Biloglav Z, Campbell S, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int. 2009 [PubMed] [Google Scholar]•
Identification of the MYH9 gene associated with serum creatinine levels in Europeans.
68. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40:1185–1192. [PMC free article] [PubMed] [Google Scholar]••
Reports of MYH9 locus associated with ESRD in African Americans accounting for a large proportion of the excess risk for ESRD observed in African Americans compared to European Americans.
69. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009;75:736–745. [PMC free article] [PubMed] [Google Scholar]••
Reports of MYH9 locus associated with ESRD in African Americans. Taken together with the other reports, the MYH9 gene is a significant genetic risk factor for CKD.
70. Freedman BI, Kopp JB, Winkler CA, Nelson GW, Rao DC, Eckfeldt JH, Leppert MF, Hicks PJ, Divers J, Langefeld CD, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol. 2009;29:626–632. [PMC free article] [PubMed] [Google Scholar]
71. Arrondel C, Vodovar N, Knebelmann B, Grunfeld JP, Gubler MC, Antignac C, Heidet L. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol. 2002;13:65–74. [PubMed] [Google Scholar]
72. Kottgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009 advanced online publication. [PMC free article] [PubMed] [Google Scholar]••
Genome-wide association study demonstrating multiple loci, GATM, JAG1, SHROOM3, STC1, and UMOD are associated with CKD and level of kidney function.
73. Hwang SJ, Yang Q, Meigs JB, Pearce EN, Fox CS. A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study. BMC Med Genet. 2007;8 Suppl 1:S10. [PMC free article] [PubMed] [Google Scholar]
74. Kottgen A, Kao WH, Hwang SJ, Boerwinkle E, Yang Q, Levy D, Benjamin EJ, Larson MG, Astor BC, Coresh J, et al. Genome-wide association study for renal traits in the Framingham Heart and Atherosclerosis Risk in Communities Studies. BMC Med Genet. 2008;9:49. [PMC free article] [PubMed] [Google Scholar]•
Identified that the EYA1, MTHFS, gene is associated with CKD progression.
75. Kottgen A, Hwang SJ, Rampersaud E, Coresh J, North KE, Pankow JS, Meigs JB, Florez JC, Parsa A, Levy D, et al. TCF7L2 variants associate with CKD progression and renal function in population-based cohorts. J Am Soc Nephrol. 2008;19:1989–1999. [PMC free article] [PubMed] [Google Scholar]•
Identifies that the TCF7L2 gene is associated with CKD progression.
76. Henderson JM, Alexander MP, Pollak MR. Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. J Am Soc Nephrol. 2009;20:961–968. [PMC free article] [PubMed] [Google Scholar]
77. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24:251–256. [PubMed] [Google Scholar]
78. Dusel JA, Burdon KP, Hicks PJ, Hawkins GA, Bowden DW, Freedman BI. Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease. Kidney Int. 2005;68:256–262. [PubMed] [Google Scholar]
79. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney Int. 2002;61:2165–2175. [PubMed] [Google Scholar]
80. Fox CS, Yang Q, Guo CY, Cupples LA, Wilson PWF, Levy D, Meigs JB. Genome-wide linkage analysis to urinary microalbuminuria in a community-based sample: The Framingham Heart Study. Kidney Int. 2005;67:70–74. [PubMed] [Google Scholar]
